Technology, injections & supplies

For once, diabetes tech is reaching people more fairly: the early signs

Early data suggests the NHS hybrid closed loop rollout is reaching deprived and minority ethnic groups far more evenly than past diabetes technology.

Written by Updated 22 May 2026 3 min read
Nurse, caregiver or healthcare worker with senior woman patient, measuring blood glucose indoors.
Photo by Getty Images on Unsplash
The 60-second answer

Diabetes technology has a bad history of reaching the people who shout loudest or live in the right postcode, and leaving others behind. Early figures from the NHS hybrid closed loop rollout in England and Wales suggest that this time is different. A hybrid closed loop, or artificial pancreas, is an insulin pump and glucose sensor that adjust background insulin automatically. So far in the rollout, the gap in uptake between the most and least deprived groups is only around 3 percent, with a similarly small gap between minority ethnic groups and white patients. That is unusually even, and it is still early days.

  • Uptake means how many eligible people actually get the technology, not just who is allowed it on paper.
  • Past diabetes tech tended to widen gaps by income, ethnicity and postcode; this rollout appears not to be doing that.
  • A roughly 3 percent gap between the most and least deprived groups is small by the standards of previous rollouts.
  • This is early data from a rollout still in progress, so it is an encouraging signal rather than a finished story.
  • Thousands of eligible people are still waiting, so if this could be you, it is worth putting yourself forward.
What happened

What the early figures show

As the national hybrid closed loop programme has rolled out across England and Wales, early analysis suggests it is reaching deprived and minority ethnic communities far more evenly than diabetes technologies have in the past. The gap in uptake between the most and least deprived groups is only around 3 percent, and the difference between minority ethnic groups and white patients is similarly small.

Part of the likely reason is how it is being done. A structured national programme, with clear criteria and a planned order, tends to spread access more evenly than the old pattern of ad hoc local funding, where the people who benefited were often those with the time, confidence or connections to push for it. This is real-world data from a live rollout, so it is an early read rather than a final verdict.

Why it matters here

Why it matters, and what you can do about it

Fairness here is not an abstract point. The people who miss out on technology are often the ones who would gain the most from it, so a rollout that closes those gaps genuinely changes lives rather than just widening a lead for people who already had good access.

The catch is that even the fairest rollout depends on people knowing they qualify and coming forward. If cost, background or your postcode have made you assume this sort of technology is not for you, this is a reason to ask again. Whatever your circumstances, it is worth asking your diabetes team whether you are eligible and where your area has got to. Do not rule yourself out on someone else’s behalf.

What to notice

Worth knowing

These are early figures from a rollout still under way, so the picture may shift as more people come on board.
Even a fair rollout relies on eligible people coming forward, so ask rather than assume you do not qualify.
Thousands who are eligible are still waiting, and different areas are moving at different paces.
If cost, background or postcode made you assume tech was not for you before, this is a reason to ask again.
What to ask your team

Questions that make an appointment useful

"Am I eligible for a hybrid closed loop system, and if so, how do I get on the list?"
"Where has my area got to with the rollout?"
"If I am not eligible yet, what would change that, and when should I ask again?"
Sources